News

The certification covers Bend’s manufacture of clinical pharmaceutical supplies for human consumption and testing of the supplies at the company’s GMP facilities. Bend Research CEO Rod Ray said,

The partnership will leverage RaQualia’s core expertise in drug discovery and development, and Interprotein’s platform technology, INTerprotein’s Engine for New Drug Design (INTENDD). Under the agreement, RaQualia will

Under the agreement, Pharmasyntez has gained rights to market and distribute Oasmia’s Paclical in Russia and the countries encompassed by the Commonwealth of Independent States (CIS). The agreement,

The once-daily nucleotide sofosbuvir plus ribavirin (RBV) was assessed in FISSION study while sofosbuvir plus ribavirin and pegylated interferon was assessed in NEUTRINO study in chronic HCV infected

The GOBIOM database assists FDA in its biomarker qualification process by providing most recent information on all the clinically evaluated, exploratory and preclinical biomarkers reported in a range

The firm’s ADCETRIS is the first in a new class of antibody-drug conjugates (ADCs) used for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic

The decree was signed by US District Court for the Northern District judge Lesley Wells of Ohio on 31 January 2013 and was issued to Ben Venue’s chief

RAVICTI used for treating Urea Cycle Disorders (UCD) in patients two years of age and older, is expected to be commercially available by the end of April 2013.

CRLX101, a tumor-targeted nanopharmaceutical, is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1a and releases camptothecin over an extended period of time. The randomized study, which is